MedTrace Logo

GLP-1 Analogs for Neuroprotection After Cardiac Arrest

NCT02442791 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2017-09-28

No results posted yet for this study

Summary

Experimental studies and previous clinical trials suggest neuroprotective effects of GLP-1 analogs in various degenerative neurological diseases, and in hypoxic brain injuries in experimental designs. This study is designed as a safety and feasibility study with patients randomized 1:1 to receive GLP-1 analogs immediately after hospital admission after out of hospital cardiac arrest.

Conditions

  • Cardiac Arrest
  • Coma

Interventions

DRUG

Byetta (Lilly, Exenatide)

See description of Arms

OTHER

20% Human Albumin

See description of Arms

Sponsors & Collaborators

  • Jesper Kjaergaard

    lead OTHER

Principal Investigators

  • Jesper Kjaergaard, MD., DMSc. · Rigshospitalet, Denmark

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02442791 on ClinicalTrials.gov